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A B S T R A C T
Despite much progress globally, TB is still one of the top 10 causes of death worldwide. Several studies
have shown the importance of implementing different preventive strategies alongside treatment of TB
disease, including BCG vaccination and treatment of latent tuberculosis infection (LTBI). Large-scale
population level LTBI treatment is not currently part of WHO guidelines which recommend LTBI
treatment only to high risk populations. Moreover, BCG has been widely used in the past decades to both
prevent infection with M. tuberculosis and reduce rates of reactivation. In this viewpoint we discuss the
hypothesis of BCG vaccination following latent TB treatment and its potential impact across different
settings.
© 2019 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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journal home page: www.elsevier .com/ locat e/ i j idThe last century has seen dramatic changes in tuberculosis (TB)
worldwide. The development of vaccination and effective antimi-
crobial treatment, combined with better living standards, led to the
decline of TB in Western Europe and North America. More recently,
the global TB epidemic has been compounded by emergence of
drug-resistant strains and co-infection with other morbidities such
as HIV and diabetes, especially in low and middle income settings.
Consequently, despite much progress globally, TB is still one of the
top 10 causes of death worldwide.
When individuals are exposed to Mycobacterium tuberculosis
and infected, they are thought to enter a non-infectious latent
stage where they can immediately progress to full-blown disease,
or spend months, years or, in the majority of cases, their whole life
with a lifelong low probability of reactivating. This probability can
be magniﬁed if they develop immunosuppression. Until recently,
the global effort to end TB has largely focussed on active TB
treatment which does not address the large pool of latently
infected individuals that is estimated to comprise at least a quarter
of the world population (Houben and Dodd, 2016). Several studies
have shown the importance of implementing different preventive
strategies alongside treatment of TB disease (Abu-Raddad et al.,
2009), including treatment of latent tuberculosis infection (LTBI)
(Ziv et al., 2001) and especially in high HIV-prevalent settings
(Mwinga et al., 1998; Lawn et al., 2010; Houben et al., 2014).* Corresponding author.
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lack of a well-established LTBI treatment success monitoring tools/
biomarkers, large-scale population level LTBI treatment is not
currently part of WHO guidelines. Current guidelines offer LTBI
treatment only to high risk populations such as HIV positive
individuals and young children (<5 years) who are contacts of
active cases, while treatment may also be considered for older
child and adult contacts (WHO, 2018). The population level impact
of targeting only a limited number of individuals is, however, likely
limited as the majority of individuals who will develop TB are not
easily identiﬁed as recent contacts and do not have HIV.
Consequently, this strategy fails to identify the large number of
TB cases that will arise from a wider pool of remotely exposed
individuals with a low risk of progression (Figure 1).
We used a simple SEEIR compartmental model of infectious
disease transmission (susceptible S, early latent Ee, late latent El,
infectious I and recovered R) with two exposed compartments, to
compare three scenarios: no LTBI treatment (yellow line), 50% of
early-latency treatment only (dark blue line) and 50% of early-
latency treatment plus 10% of late latent treatment (green line).
Early-latency treatment is not enough to concretely reduce the
number of active TB infections. However, because of the high
number of late-latency infections in the populations, even treating
a small percentage of them would mean treating a very high
number of individuals, which is rarely a realistic scenario.
Studies (Stagg et al., 2014) have shown that short duration
rifamycin based therapy is more efﬁcacious than other approaches
at preventing active TB. However the effects of large-scaleious Diseases. This is an open access article under the CC BY-NC-ND license (http://
Figure 1. An example of LTBI treatment in a population.
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run, particularly in highly endemic settings. Uncertainty exists in
relation to our inability to deﬁne LTBI cure, one exploratory study
(Biraro et al., 2015) showed that isoniazid preventive therapy led to
effects on the immune response to M. tuberculosis, however
decreased levels of cytokines and antibodies are not enough to
predict the complete clearance of TB infection. Both tuberculin skin
test (TST) and interferon-F release assay (IGRA) cannot distinguish
current infection from prior remote exposure, and test results
continue to be positive even after LTBI treatment completion.
Furthermore, LTBI treatment does not offer protection against
reinfection, limiting the durability of protection in regions
characterised by high force of infection (e.g. mines).
Our previous work has shown that BCG is highly efﬁcacious if
given to individuals who are not already infected with M.
tuberculosis, determined by absence of a response to tuberculin
(Mangtani et al., 2014; Abubakar et al., 2013). This systematic
review speciﬁcally demonstrated that the absence of prior M.
tuberculosis infection or sensitization with environmental myco-
bacteria is associated with higher efﬁcacy of BCG against
pulmonary tuberculosis and possibly against miliary and menin-
geal tuberculosis. BCG does not work in those known to be infected
by M. tuberculosis. The inference from this analysis is that prior
infection to M. tuberculosis blocks or masks the effect of BCG
vaccination. It is therefore reasonable to hypothesise that there
may be a different immune response to BCG vaccination among
individuals who have completed treatment for LTBI, compared to
people with untreated LTBI. In this case, it is possible to suggest
that the clearance of M. tuberculosis infection might inﬂuence the
‘unblocking’ of the protective immune response induced by BCG
vaccination. Preclearance of M. tuberculosis is heterogeneous
(some individuals will effectively have M. tuberculosis cleared
while it will be residual in others), a recent small underpowered
study (Suliman et al., 2016) has suggested that it has little effect on
the classical lymphocyte immune response, but highlighted a
surprising durability of memory NKT-like and NK cells after BCG
revaccination. Moreover, ensuring the individual status related to
infection prior to BCG vaccination is also important in preventing
skin reactions such as Koch-like reactions.
A recent trial found that BCG revaccination works as well as a
novel vaccine (H4:IC31) in preventing sustained IGRA conversion
(Nemes et al., 2018) among IGRA-negative individuals, although
the authors acknowledged that there is no deﬁnitive test for
acquisition, persistence, or clearance of M. tuberculosis infection.
This raises a research question on whether BCG vaccination or
revaccination may confer protection to those individuals who
successfully obtain clearance of M. tuberculosis using a rifamycin-
based regimen. There are several reasons why this strategy, if
successful, will contribute to ending the global TB epidemic.First, immunisation with BCG is one of the most common TB
interventions, particularly in children in endemic settings where it
is usually part of the childhood immunization program. Roy et al.
(2014) showed that, while it offers limited protection against
infection, it offers 71% protection against disease and a duration of
effect of 10–15 years. Exploring the impact of BCG vaccination
following LTBI treatment at a population level would provide a
further avenue to strengthen TB control.
Second, in high-incidence countries the number of people
latently infected is high and, while mass treatment of these
individuals with a positive IGRA or TST is not realistic, even if LTBI
treatment is limited to direct contacts of active cases, vaccination
post treatment may protect them from re-infection in a high
transmission setting for another 10–20 years.
The combination of LTBI treatment and BCG vaccination could
also be offered to other high risk populations. In the speciﬁc case of
mine workers, for example, if vaccine coverage is sufﬁciently high,
this could potentially create herd immunity. Other risk groups such
as individuals affected by diabetes and silicosis may also beneﬁt
from this strategy. A combined LTBI treatment BCG vaccination
strategy could also have a positive impact in countries with high
prevalence of drug-resistant strains. An effective preventive
treatment could avoid longer, more expensive treatments in cases
of multi-drug resistant and extensively drug-resistant strains.
In low-incidence countries, high risk groups include migrants,
drug users and those with a history of incarceration. While the
force of infection in the general population is very low, in some of
these high risk groups, levels of transmission can be very high
(Sacchi et al., 2015; Carbone et al., 2015). If the majority of
individuals originating from high-incidence countries resides in
the same area, there can also be ongoing transmission within these
households which may be prevented by a BCG post LTBI treatment
strategy.
The search for new tools to end the TB epidemic will require us
to revisit the use of existing tools and ensure maximal beneﬁt is
obtained. While our hypothesis is supported by a range of related
observations, only a trial to establish protection by BCG following
latent TB treatment can conﬁrm this.
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